Jefferies Downgrades Milestone Pharmaceuticals to Hold, Lowers Price Target to $4
Portfolio Pulse from richadhand@benzinga.com
Jefferies analyst Chris Howerton downgraded Milestone Pharmaceuticals (NASDAQ:MIST) from Buy to Hold and lowered the price target from $8 to $4.
June 20, 2023 | 8:58 am
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Milestone Pharmaceuticals (NASDAQ:MIST) was downgraded from Buy to Hold by Jefferies analyst Chris Howerton, with a reduced price target of $4.
The downgrade from Buy to Hold and the reduction in price target from $8 to $4 by Jefferies analyst Chris Howerton indicate a less optimistic outlook for Milestone Pharmaceuticals. This could negatively impact the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100